[company_age]8.0[/company_age][employees]11-50 employees[/employees][funding]Series A[/funding][description]Dxcover is a clinical-stage liquid biopsy company pioneering the early detection of multiple cancers through infrared spectroscopy of circulating pan-omic biomarkers. They have generated compelling clinical data with high accuracy detection of Stage I and II cancers. Dxcover is headquartered in Scotland, UK, with operations in the USA. \n\nDxcover's mission is to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. They believe that early diagnosis is crucial for improving patient outcomes and reducing the burden of cancer. \n\nDxcover's platform has the potential to revolutionize cancer diagnostics by providing a fast, accurate, and non-invasive method for early detection. The company is currently conducting clinical trials for its liquid biopsy test for the detection of brain, colorectal, and lung cancer. \n\nDxcover is a company with a strong commitment to innovation and collaboration. They have a team of experienced scientists and engineers who are passionate about developing new technologies to improve human health. Dxcover is also actively involved in partnerships with leading academic and medical institutions. \n\nDxcover is a company to watch in the field of cancer diagnostics. Their innovative technology and commitment to early detection have the potential to make a significant impact on the lives of cancer patients.[/description][ps]Liquid biopsy tests for early cancer detection[/ps]